Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Applied entered fiscal 2027 with strong operating momentum: fiscal-fourth-quarter sales increased 10.4%, organic sales increased 9.7%, and management estimated first-quarter-to-date organic growth near 7%. The company guides to 4.0%-6.5% fiscal-2027 sales growth, $11.65-$12.15 diluted EPS, and a 12.5%-12.8% EBITDA margin while targeting $7 billion of sales and a 14% EBITDA margin within five years. These operating signals support a constructive business outlook. A Hold recommendation therefore reflects favorable execution balanced against macroeconomic, trade-policy, inflation, acquisition-execution, and unanchored valuation risk.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026
Low · most bearish analyst$390.00
Mean target$400.00
High · most bullish analyst$420.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$390.0020%

Macroeconomic weakness, trade-policy disruption, inflation, difficult comparisons, or slower industrial investment reduces fiscal-2027 sales growth below 4.0%. EBITDA margin falls below 12.5%, EPS misses $11.65, and slower acquisition or internal-initiative execution delays the five-year objectives.

Base CaseCentral scenario
$400.0055%
Matches the consensus mean

Fiscal-2027 sales growth remains within management's 4.0%-6.5% range, diluted EPS falls within $11.65-$12.15, and EBITDA margin remains within 12.5%-12.8%. The five-year $7 billion sales and 14% margin objectives remain credible but depend on macro conditions, acquisitions, and internal execution.

Bull CaseUpside scenario
$420.0025%

Demand recovery and structural spending on technical MRO, automation, industrial-system upgrades, and critical infrastructure drive sales above the 6.5% upper end of fiscal-2027 guidance. Continued operating leverage lifts EBITDA margin above 12.8%, and sustained cash generation supports disciplined acquisitions.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Fiscal-fourth-quarter organic sales grew 9.7%, including 12.9% growth in Engineered Solutions and 7.9% in Service Center, while management estimated fiscal-first-quarter-to-date organic growth near 7%.
  • Management guides to a 12.5%-12.8% fiscal-2027 EBITDA margin and targets a 14% margin within five years, supported by mix, internal initiatives, and operating leverage.
  • Fiscal-2026 free cash flow was $460.5 million, and management identifies balance-sheet capacity and an active acquisition pipeline as potential long-term growth compounding mechanisms.
Sign in / Sign up to read more
Key Investment Risks
  • Fiscal-2027 guidance explicitly incorporates geopolitical uncertainty, trade-policy dynamics, inflationary pressure, and growth investments.
  • Management cautioned that year-over-year comparisons become more difficult as fiscal 2027 progresses, creating deceleration risk after the strong fiscal-fourth-quarter result.
  • The $7 billion sales and 14% EBITDA-margin objectives depend on macroeconomic conditions, acquisition timing and scope, and successful execution of internal initiatives.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.